Format

Send to

Choose Destination
Expert Opin Investig Drugs. 2019 Jun;28(6):525-543. doi: 10.1080/13543784.2019.1627324. Epub 2019 Jun 12.

Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials.

Author information

1
a Department of Neurology , University of Michigan , Ann Arbor , MI , USA.
2
b Program for Neurology Research & Discovery , University of Michigan , Ann Arbor , MI , USA.

Erratum in

Abstract

INTRODUCTION:

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of cortical, brainstem, and spinal motor neurons; it causes progressive muscle weakness and atrophy, respiratory failure, and death. No currently available treatment either stops or reverses this disease. Therapeutics to slow, stop, and reverse ALS are needed. Stem cells may be a viable solution to sustain and nurture diseased motor neurons. Several early-stage clinical trials have been launched to assess the potential of stem cells for ALS treatment. Areas covered: Expert opinion:

AREAS COVERED:

This review covers the key advances from early phase clinical trials of stem cell therapy for ALS and identifies promising avenues and key challenges.

EXPERT OPINION:

Clinical trials in humans are still in the nascent stages of development. It will be critical to ensure that powered, well-controlled trials are conducted, that optimal treatment windows are identified, and that the ideal cell type, cell dose, and delivery site and method are determined. Several trials have used more invasive procedures, and ethical concerns of sham procedures on patients in the control arm and on their safety should be considered.

KEYWORDS:

ALS; Amyotrophic lateral sclerosis; clinical trial; preclinical; stem cells; therapy

PMID:
31189354
PMCID:
PMC6697143
[Available on 2020-06-12]
DOI:
10.1080/13543784.2019.1627324
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center